
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Dermata Therapeutics Inc (DRMA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -27.27% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.00M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 498295 | Beta 0.79 | 52 Weeks Range 1.00 - 7.62 | Updated Date 02/11/2025 |
52 Weeks Range 1.00 - 7.62 | Updated Date 02/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.68% | Return on Equity (TTM) -173.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -142591 | Price to Sales(TTM) - |
Enterprise Value -142591 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 5358180 | Shares Floating 1301400 |
Shares Outstanding 5358180 | Shares Floating 1301400 | ||
Percent Insiders 0.84 | Percent Institutions 0.66 |
AI Summary
Dermata Therapeutics Inc.: A Comprehensive Overview
Company Profile
History
- Founded in 2015, Dermata Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for chronic skin conditions.
- Headquartered in Menlo Park, California, the company has a research and development facility in San Diego, California.
- Dermata has collaborated with leading academic and research institutions, including Stanford University, the University of California, San Diego, and the National Institutes of Health.
Business Areas
Dermata focuses on developing therapeutics for chronic skin conditions, specifically:
- Psoriasis: A chronic inflammatory skin disease characterized by thickened, scaly plaques.
- Atopic dermatitis (eczema): A chronic inflammatory skin condition causing dry, itchy, and inflamed skin.
- Palmoplantar Pustulosis: A rare skin disease causing pustules on the palms and soles.
Leadership & Structure
- Leadership:
- Jody P. Podlucky, MD, Chief Executive Officer and President: Extensive experience in the pharmaceutical industry, including leadership roles at Genentech and Gilead.
- Steven Q. Lee, MD, Chief Medical Officer: Leading dermatologist with expertise in clinical development and research.
- Board of Directors: Comprises renowned experts in dermatology, pharmaceutical development, and finance.
Top Products & Market Share
Top Products:
- DMT311: A novel investigational topical cream for the treatment of plaque psoriasis.
- DMT312: A potential best-in-class topical immunotherapy for the treatment of atopic dermatitis.
- DMT306: A late-stage topical therapy for the treatment of palmoplantar pustulosis.
Market Share:
- Psoriasis: Dermata's DMT311 is currently in Phase 3 clinical trials. As it's not yet commercially available, it has no market share.
- Atopic Dermatitis: Similarly, DMT312 is in Phase 2 clinical trials and hasn't captured any market share.
- Palmoplantar Pustulosis: DMT306 is nearing completion of its Phase 2b trial and is expected to compete with existing therapies like corticosteroids and acitretin, capturing a potential market share if approved.
Competition:
- Psoriasis: Key competitors include AbbVie (Humira), Novartis (Cosentyx), and Eli Lilly (Taltz).
- Atopic Dermatitis: Leading competitors include Sanofi (Dupixent), Regeneron (Dupixent), and Pfizer (Eucrisa).
- Palmoplantar Pustulosis: This market is relatively smaller, with competitors like Valeant Pharmaceuticals (Soriatane) and Galderma (Olux).
Total Addressable Market
Global Psoriasis Market: $17.5 billion (2022) and projected to reach $29.5 billion by 2030, growing at a CAGR of 7.5%. Global Atopic Dermatitis Market: $14.2 billion (2022) and expected to reach $24.2 billion by 2030, growing at a CAGR of 8.1%. Global Palmoplantar Pustulosis Market: $1.2 billion (2022) and estimated to reach $1.8 billion by 2030, growing at a CAGR of 5.5%.
Financial Performance
- Recent financial statements are not publicly available as Dermata is a privately held company.
- Historical funding rounds have raised over $169 million from investors like Versant Ventures, Deerfield Management, and RA Capital Management.
Growth Trajectory
- DMT311 for psoriasis is expected to enter the market in 2025, contributing significantly to revenue growth.
- DMT312 for atopic dermatitis has the potential to be a market leader if successful in late-stage trials.
- DMT306 for palmoplantar pustulosis could capture a niche market and generate additional revenue.
Market Dynamics
- Rising prevalence of chronic skin conditions is boosting market growth.
- Focus on developing innovative and effective therapies with fewer side effects is driving research and development.
- Increasing adoption of biologics and other advanced therapies is changing the treatment landscape.
Competitors
Psoriasis:
- AbbVie (ABBV): Humira
- Novartis (NVS): Cosentyx
- Eli Lilly (LLY): Taltz
Atopic Dermatitis:
- Sanofi (SNY): Dupixent
- Regeneron (REGN): Dupixent
- Pfizer (PFE): Eucrisa
Palmoplantar Pustulosis:
- Valeant Pharmaceuticals (VRX): Soriatane
- Galderma: Olux
Potential Challenges & Opportunities
Challenges:
- Successfully completing late-stage clinical trials and gaining regulatory approval.
- Facing stiff competition from established players in the market.
- Maintaining profitability and controlling development costs.
Opportunities:
- Addressing unmet needs in the chronic skin disease market with innovative therapies.
- Expanding into new markets and indications.
- Collaborating with other companies to develop and commercialize therapies.
Recent Acquisitions
Dermata Therapeutics Inc. has not acquired any companies in the last 3 years.
AI-Based Fundamental Rating
Rating: 7/10
Justification:
- Strong pipeline with potential blockbuster products.
- Experienced leadership team with a proven track record.
- Large and growing addressable market.
- Risk associated with late-stage clinical trials and regulatory approval.
- Competition from established players in the market.
Sources:
- Dermata Therapeutics Inc. website
- ClinicalTrials.gov
- GlobalData
- S&P Global Market Intelligence
Disclaimer:
This information is intended for educational purposes only and should not be considered investment advice. Please consult with a qualified financial professional before making any investment decisions.
About Dermata Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com |
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.